These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26609516)

  • 1. Biomarker-directed Targeted Therapy in Colorectal Cancer.
    Carethers JM
    J Dig Cancer Rep; 2015 Jun; 3(1):5-10. PubMed ID: 26609516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in colorectal cancer: Current clinical utility and future perspectives.
    Vacante M; Borzì AM; Basile F; Biondi A
    World J Clin Cases; 2018 Dec; 6(15):869-881. PubMed ID: 30568941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
    Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
    World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
    Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
    Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
    Carethers JM; Jung BH
    Gastroenterology; 2015 Oct; 149(5):1177-1190.e3. PubMed ID: 26216840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer.
    Kubota N; Taniguchi F; Nyuya A; Umeda Y; Mori Y; Fujiwara T; Tanioka H; Tsuruta A; Yamaguchi Y; Nagasaka T
    Oncol Lett; 2020 Apr; 19(4):2685-2694. PubMed ID: 32218819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.
    Dienstmann R; Salazar R; Tabernero J
    Am Soc Clin Oncol Educ Book; 2014; ():91-9. PubMed ID: 24857065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of microsatellite status on chemotherapy for colorectal cancer patients with
    Huang CJ; Huang SH; Chien CC; Lee HH; Yang SH; Chang CC; Lee CL
    Oncol Lett; 2016 Dec; 12(6):4427-4434. PubMed ID: 28101205
    [No Abstract]   [Full Text] [Related]  

  • 18. Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test.
    Alqahtani M; Grieu F; Carrello A; Amanuel B; Mashour M; Alattas R; Alsaleh K; Alsheikh A; Alqahtani S; Iacopetta B
    Asian Pac J Cancer Prev; 2016; 17(4):1917-23. PubMed ID: 27221876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.